A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Etrasimod (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CULTIVATE
- Sponsors Arena Pharmaceuticals
- 20 Nov 2019 Status changed from planning to not yet recruiting.
- 07 Nov 2019 According to an Arena Pharmaceuticals media release, the company is on track to initiate this study this year.
- 16 Aug 2018 New trial record